Clario Expands Its Leadership in Real-World Data Collection Through a New Partnership with ActiGraph, a Leader in Activity Tracking and Wearables

Collaboration will improve patient experience and study efficiency with wearable technology – while capturing a wider range of activity and sleep data

    • Clario will offer ActiGraph technologies to its customers to complement its suite of eCOA, Precision Motion, Cardiac Safety, Respiratory, Medical Imaging and Trial Enablement solutions
    • Clario’s flagship Precision Motion offering, the Opal V2C® System, delivers high-fidelity data and analytics that can accelerate study start-up times and provide deeper insights into functional mobility.
    • ActiGraph’s wearable medical-grade, FDA-cleared technology captures objective, real-world biometric data related to physical activity, mobility, sedentary behavior and sleep
    • ActiGraph’s wearable technology enables clinical trial sponsors to increase the accuracy of continuous passive monitoring and the quality of clinical data through real-time digital capture of objective parameters related to activities of daily living and measurements quality of life

PHILADELPHIA CREAM, June 16, 2022 /PRNewswire/ — Clariona technology company that provides leading endpoint solutions for decentralized, hybrid and onsite clinical trials (DCTs), today announced its partnership with ActiGraph, a pioneer and leading provider of wearable activity detection technologies, to expand its already extensive evidence generation platform and decentralization technology portfolio. The partnership will help clinical trial sites and sponsors improve efficiency and accuracy while increasing convenience for study participants. Clario will offer ActiGraph technologies to its customers in addition to its suite of eCOA, Precision Motion, Cardiac Safety, Respiratory, Medical Imaging and Trial Enablement solutions.

Quality of life is increasingly considered a critical patient-reported outcome (PRO) by regulatory bodies as they seek evidence of how clinical interventions change the way patients feel overall . Therefore, activity-related parameters are needed in clinical studies in many therapeutic areas (including oncology, neuroscience, cardiovascular disease, diabetes, obesity, and sleep disorders) where patients could manage their conditions for an extended period. Historically, this requirement has placed a burden on study participants who are asked to submit subjective patient reports. In contrast, ActiGraph’s FDA-cleared, medical-grade platform captures objective, real-world biometric data related to physical activity, mobility, sedentary behavior, and sleep. With the proper data science and validation support from ActiGraph and Clario, these data can truly empower clinical trial sponsors to increase the accuracy, quality, and completeness of clinical data by increasing reporting. patient subjective and point-in-time clinical outcome data with continuous numerical measures. .

“We are at an inflection point. Regulatory agencies and patients expect clinical interventions to prolong quality, not just lifespan,” said Ellen Street, EVP Cardiac Safety and Precision Motion at Clario. “Our partnership with ActiGraph allows us to provide our customers with a broader range of measurable and meaningful patient-meaningful quality of life metrics and is the next step in how we aim to transform lives through technologies that generate the richest clinical evidence. »

Ellen went on to say, “Quality of life parameters such as movement and sleep are best measured over long periods of time and across a range of settings. Decentralized clinical trials can make the most of these metrics and help bring life-enhancing therapies to market. We’re proud to offer our customers another key technology that not only enables DCTs, but also makes patient engagement and site responsibilities less burdensome and activity-related data more accurate.

Leveraging over 20 years of real-world data capture expertise, ActiGraph’s ecosystem of wearable biosensors, software tools, and scientific services delivers near real-time digital data through a flexible, cloud-based technology platform designed around the challenges and complexities of the clinical development process. ActiGraph’s technologies, combined with Clario’s depth of scientific expertise, global scale and existing capacity to collect data on a wide range of parameters, will help ensure complex global trials run smoothly, whether on-premises, decentralized or hybrid.

“The combination of high-fidelity handhelds deployed on our CentrePoint platform with a state-of-the-art eCOA tool represents an opportunity to improve the patient experience in modern clinical trials,” said Jeremy Wyatt, CEO of ActiGraph. “The most accurate picture of a patient’s experience comes from a combination of self-reported and high-integrity objective measures. Our teams are excited to begin leveraging Clario’s expertise and providing pharmaceutical companies and biotechnology our technological and scientific resources, as we both work to advance the development of drugs and therapies.”

About ActiGraph

Founded in 2004, ActiGraph is a leading wearable technology partner in the pharmaceutical and academic life sciences research industries. ActiGraph’s biosensor solutions have been deployed in hundreds of industry-sponsored clinical drug trials and continue to lead the way in real-world remote monitoring in this complex and highly regulated space. With over 2,000 customers in over 110 countries and referenced in approximately 20,000 peer-reviewed articles, ActiGraph has earned its reputation as the “Gold Standard” in objective business measurement.

For more information, visit ActiGraphCorp.com or follow us on LinkedIn Where Twitter.

About Clario

Clarion is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotechnology and medical device partners. Through decentralized and on-site trials, our deep scientific expertise, global scale, and industry’s broadest endpoint technology platform enable our partners to transform lives. Clario’s Try Anywhere™ The solutions have powered hybrid and decentralized clinical trials (DCTs) for more than 15 years, enabling sponsors to collect high-quality endpoint data from any modality or location, while improving the experience and diversity of patients. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision movement and respiratory parameters. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts have helped deliver more than 19,000 trials and 870 regulatory approvals for more than 5 million patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.

For more information, visit Clario.com or follow us on LinkedIn Where Twitter.

Clario Media Contact
Duncan Cantor
Senior Director, Corporate Communications
[email protected]

SOURCEClario

Comments are closed.